Agency Information Collection Activities: Proposed Collection; Comment Request, 495-496 [2015-33221]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 3 / Wednesday, January 6, 2016 / Notices
Laboratory Services, a Division of
LabOne, Inc.)
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088, Testing for Veterans Affairs
(VA) Employees Only
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774 (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509–755–8991/
800–541–7891x7
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432 (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories)
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370 (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory,
3700650 Westwind Blvd., Santa Rosa,
CA 95403, 800–255–2159
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
STERLING Reference Laboratories, 2617
East L Street, Tacoma, Washington
98421, 800–442–0438
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only
*The Standards Council of Canada
(SCC) voted to end its Laboratory
VerDate Sep<11>2014
17:32 Jan 05, 2016
Jkt 238001
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Summer King,
Statistician.
[FR Doc. 2015–33222 Filed 1–5–16; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
1243.
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
495
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Services Grant
Program for Residential Treatment for
Pregnant and Postpartum Women
(PPW) Quarterly Progress Reports—
NEW
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Treatment, has developed a set of
infrastructure development measures in
which recipients of cooperative
agreements will report on various
benchmarks on a quarterly-annual basis.
The infrastructure development
measures are designed to collect
information at the grantee-level and
program-level.
The draft infrastructure measures are
based on the programmatic
requirements conveyed in TI–14–005,
Services Grant Program for Residential
Treatment for Pregnant and Postpartum
Women.
The purpose of this program is to
provide funding to improve treatment
for low-income (according to federal
poverty guidelines) women, age 18 and
over, who are pregnant, postpartum (the
period after childbirth up to 12 months),
and their minor children, age 17 and
under, who have limited access to
quality health services.
The pregnant and postpartum women
program will implement parenting and
treatment evidence-based practice
models and a feedback loop developed
to enable the grantee and the programs
to identify barriers and test solutions
through direct services. The expected
outcomes of these grants will include
decreases in the use and/or abuse of
prescription drugs, alcohol, tobacco,
illicit and other harmful drugs (e.g.,
inhalants) among pregnant and
postpartum women; increases in safe
and healthy pregnancies; improved
birth outcomes; reduced perinatal and
environmentally-related effects of
maternal and/or paternal drug abuse on
infants and children; improved mental
and physical health of women and
children; prevention of mental,
E:\FR\FM\06JAN1.SGM
06JAN1
496
Federal Register / Vol. 81, No. 3 / Wednesday, January 6, 2016 / Notices
emotional, and behavioral disorders
among the children; improved parenting
skills, family functioning, economic
stability, and quality of life; decreased
involvement in and exposure to crime,
violence, and neglect; and decreased
physical, emotional, and sexual abuse
for all family members. Women, their
adolescents/children (up to age 17),
fathers, and other family members who
are provided services through grant
funds will inform the process to
improve systems issues.
ANNUAL DATA COLLECTION BURDEN DATA COLLECTION BURDEN
Instrument/activity
Number of
respondents
Responses
per
respondent
Total
responses
Hours per
response
Total hour
burden
Progress Report ...................................................................
25
4
100
8
800
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
Room 2–1057, One Choke Cherry Road,
Rockville, MD 20857 or email her a
copy at summer.king@samhsa.hhs.gov.
Written comments should be received
by March 7, 2016.
Summer King,
Statistician.
[FR Doc. 2015–33221 Filed 1–5–16; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Notice of Issuance of Final
Determination Concerning Certain
Multifunction Printer Products
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of final determination.
AGENCY:
This document provides
notice that U.S. Customs and Border
Protection (‘‘CBP’’) has issued a final
determination concerning the country of
origin of certain multifunction printer
products known as bizhub C3850FS
multifunction digital printers (‘‘bizhub
MFP’’). Based upon the facts presented,
CBP has concluded that the country of
origin of the bizhub MFP is Japan for
purposes of U.S. Government
procurement.
SUMMARY:
The final determination was
issued on December 23, 2015. A copy of
the final determination is attached. Any
party-at-interest, as defined in 19 CFR
177.22(d), may seek judicial review of
this final determination within February
5, 2016.
FOR FURTHER INFORMATION CONTACT:
Antonio J. Rivera, Valuation and Special
Programs Branch, Regulations and
Rulings, Office of International Trade
(202) 325–0226.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that on December 23, 2015,
mstockstill on DSK4VPTVN1PROD with NOTICES
DATES:
VerDate Sep<11>2014
17:32 Jan 05, 2016
Jkt 238001
pursuant to subpart B of part 177, U.S.
Customs and Border Protection
Regulations (19 CFR part 177, subpart
B), CBP issued a final determination
concerning the country of origin certain
multifunction printer products known
as bizhub C3850FS multifunction digital
printers, which may be offered to the
U.S. Government under an
undesignated government procurement
contract. This final determination, HQ
263561, was issued under procedures
set forth at 19 CFR part 177, subpart B,
which implements title III of the Trade
Agreements Act of 1979, as amended
(19 U.S.C. 2511–18). In the final
determination, CBP concluded that the
processing in Japan resulted in a
substantial transformation. Therefore,
the country of origin of the bizhub MFP
is Japan for purposes of U.S.
Government procurement.
Section 177.29, CBP Regulations (19
CFR 177.29), provides that a notice of
final determination shall be published
in the Federal Register within 60 days
of the date the final determination is
issued. Section 177.30, CBP Regulations
(19 CFR 177.30), provides that any
party-at-interest, as defined in 19 CFR
177.22(d), may seek judicial review of a
final determination within 30 days of
publication of such determination in the
Federal Register.
Dated: December 23, 2015.
Myles B. Harmon,
Acting Executive Director, Regulations and
Rulings, Office of International Trade.
Attachment
HQ H263561
December 23, 2015
OT:RR:CTF:VS H263561 AJR
CATEGORY: Origin
Daniel E. Waltz, Esq., Squire Patton Boggs
(US) LLP, 2550 M Street, NW., Washington,
DC 20037
RE: U.S. Government Procurement; Country
of Origin of Multifunction Printers;
Substantial Transformation
Dear Mr. Waltz: This is in response to your
letter, dated March 23, 2015, requesting a
final determination on behalf of Konica
Minolta (‘‘K/M’’), pursuant to subpart B of
part 177 of the U.S. Customs and Border
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Protection (‘‘CBP’’) Regulations (19 CFR part
177). Under these regulations, which
implement Title III of the Trade Agreements
Act of 1979 (‘‘TAA’’), as amended (19 U.S.C.
2511 et seq.), CBP issues country of origin
advisory rulings and final determinations as
to whether an article is or would be a product
of a designated country or instrumentality for
the purposes of granting waivers of certain
‘‘Buy American’’ restrictions in U.S. law or
practice for products offered for sale to the
U.S. Government.
This final determination concerns the
country of origin of K/M’s bizhub C3850FS
multifunction digital printers (‘‘bizhub
MFP(s)’’). We note that K/M is a party-atinterest within the meaning of 19 CFR
177.22(d)(1) and is entitled to request this
final determination.
FACTS:
K/M plans to sell its bizhub MFPs to the
U.S. government. The bizhub MFPs are
multifunction color machines that perform
printing, copying, scanning, and faxing
functions. According to K/M’s counsel, the
bizhub MFP was designed and developed in
Japan, and its most important and complex
components will be manufactured in Japan.
The assembly process for the bizhub MFPs
will start in Thailand and finish in Japan,
assembling a total of 11 subassemblies into
the final bizhub MFP product.
Assembly Processes in Thailand:
In Thailand, the following four
subassemblies (collectively, ‘‘Subassemblies
1–4’’) will be assembled into their final form
within the bizhub MFP’s frame:
1. The Print Head will be produced in
Thailand from five sub-components:
• a G1 lens manufactured in Japan;
• a G2 lens manufactured in Japan;
• a polygonal motor manufactured in
China;
• a housing case manufactured in China;
and,
• a laser diode manufactured in Taiwan.
According to K/M’s counsel, while the
quantity at which the G1 and G2 lenses are
produced lowers their relative cost, the
lenses are more complex than the other subcomponents of the Print Head as noted by the
higher skill and technology levels needed to
produce them. The Print Head operates by
reflecting a laser beam off of the lenses and
onto the rotating polygonal mirrors in order
to produce a copied image in the Latent
Image Unit’s photoconductor (‘‘OPC’’). The
Print Head will be assembled into, and
E:\FR\FM\06JAN1.SGM
06JAN1
]]>Agencies
[Federal Register Volume 81, Number 3 (Wednesday, January 6, 2016)]
[Notices]
[Pages 495-496]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-33221]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning opportunity for public comment on
proposed collections of information, the Substance Abuse and Mental
Health Services Administration (SAMHSA) will publish periodic summaries
of proposed projects. To request more information on the proposed
projects or to obtain a copy of the information collection plans, call
the SAMHSA Reports Clearance Officer at (240) 276-1243.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Services Grant Program for Residential Treatment for
Pregnant and Postpartum Women (PPW) Quarterly Progress Reports--NEW
The Substance Abuse and Mental Health Services Administration
(SAMHSA), Center for Substance Abuse Treatment, has developed a set of
infrastructure development measures in which recipients of cooperative
agreements will report on various benchmarks on a quarterly-annual
basis. The infrastructure development measures are designed to collect
information at the grantee-level and program-level.
The draft infrastructure measures are based on the programmatic
requirements conveyed in TI-14-005, Services Grant Program for
Residential Treatment for Pregnant and Postpartum Women.
The purpose of this program is to provide funding to improve
treatment for low-income (according to federal poverty guidelines)
women, age 18 and over, who are pregnant, postpartum (the period after
childbirth up to 12 months), and their minor children, age 17 and
under, who have limited access to quality health services.
The pregnant and postpartum women program will implement parenting
and treatment evidence-based practice models and a feedback loop
developed to enable the grantee and the programs to identify barriers
and test solutions through direct services. The expected outcomes of
these grants will include decreases in the use and/or abuse of
prescription drugs, alcohol, tobacco, illicit and other harmful drugs
(e.g., inhalants) among pregnant and postpartum women; increases in
safe and healthy pregnancies; improved birth outcomes; reduced
perinatal and environmentally-related effects of maternal and/or
paternal drug abuse on infants and children; improved mental and
physical health of women and children; prevention of mental,
[[Page 496]]
emotional, and behavioral disorders among the children; improved
parenting skills, family functioning, economic stability, and quality
of life; decreased involvement in and exposure to crime, violence, and
neglect; and decreased physical, emotional, and sexual abuse for all
family members. Women, their adolescents/children (up to age 17),
fathers, and other family members who are provided services through
grant funds will inform the process to improve systems issues.
Annual Data Collection Burden Data Collection Burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Responses per Total Hours per Total hour
Instrument/activity respondents respondent responses response burden
--------------------------------------------------------------------------------------------------------------------------------------------------------
Progress Report.................................................... 25 4 100 8 800
--------------------------------------------------------------------------------------------------------------------------------------------------------
Send comments to Summer King, SAMHSA Reports Clearance Officer,
Room 2-1057, One Choke Cherry Road, Rockville, MD 20857 or email her a
copy at summer.king@samhsa.hhs.gov. Written comments should be received
by March 7, 2016.
Summer King,
Statistician.
[FR Doc. 2015-33221 Filed 1-5-16; 8:45 am]
BILLING CODE 4162-20-P
